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Abstract
Background: Lentiviral vectors (LVs) can efficiently transduce a broad spectrum of cells and tissues, including
dividing and non-dividing cells. So far the most widely used method for concentration of lentiviral particles is
ultracentrifugation (UC).
An important feature of vectors derived from lentiviruses and prototypic gamma-retroviruses is that the host range
can be altered by pseudotypisation. The most commonly used envelope protein for pseudotyping is the
glycoprotein of the Vesicular Stomatitis Virus (VSV.G), which is also essential for successful concentration using UC.
Results: Here, we describe a purification method that is based on membrane adsorbers (MAs). Viral particles are
efficiently retained by the anionic exchange MAs and can be eluted with a high-salt buffer. Buffer exchange and
concentration is then performed by utilizing ultrafiltration (UF) units of distinct molecular weight cut off (MWCO).
With this combined approach similar biological titers as UC can be achieved (2 to 5 × 10
9 infectious particles (IP)/
ml). Lentiviral particles from small starting volumes (e.g. 40 ml) as well as large volumes (up to 1,000 ml) cell
culture supernatant (SN) can be purified. Apart from LVs, vectors derived from oncoretroviruses can be efficiently
concentrated as well. Importantly, the use of the system is not confined to VSV.G pseudotyped lenti- and retroviral
particles and other pseudotypes can also be purified.
Conclusions: Taken together the method presented here offers an efficient alternative for the concentration of
lenti- as well as retroviral vectors with different pseudotypes that needs no expensive equipment, is easy to handle
and can be used to purify large quantities of viral vectors within a short time.
Background
Lentiviral vectors (LVs) are versatile tools for molecular
medicine and gene therapy [1]. They are able to inte-
grate their viral genome into both dividing and non-
dividing cells [2,3]. Most LVs presently used are based
on the human immunodeficiency virus type 1 (HIV-1),
which is the most extensively studied lentivirus [1]. In
addition, lentivectors have been derived from a variety
of other lentiviruses (e.g. simian, equine and feline lenti-
viruses) [4].
Lenti- as well as spuma- and oncoretroviruses belong
to the large family of Retroviridae [5]. Retroviruses are -
besides adenoviruses - the most widely used vectors in
gene therapy clinical trials (http://www.wiley.co.uk/
genmed/clinical). They were also the first vectors that
have been applied in gene therapy. Most oncoretroviral
vectors are based on the Moloney murine leukemia
virus (MoMLV) [6]. The wild type MoMLV and retro-
viral vectors carrying the original MoMLV envelope
proteins transduce only cells that express the ecotropic
receptor, i. e. rodent cells [7,8]. However, oncoretroviral
vectors are sensitive to environmental conditions and
lose their infectivity relatively quickly [9,10] resulting in
a loss of infectious particles (IP) during purification [11].
Lenti- as well as retroviral vectors can also be pseudo-
typed with different envelope proteins from other
viruses resulting in different characteristics of the vec-
tors, either regarding their surface charge, physical stabi-
lity and/or biological activity [11]. Pseudotyping of LVs
or oncoretroviral vectors with VSV.G broadens the host
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mediated endocytosis [12]. Furthermore, VSV.G-pseudo-
typed viral vectors were shown to be more stable and
can be concentrated by ultracentrifugation (UC) without
a significant loss in titer [13,14].
The most commonly used retro- as well as lentiviral
vector systems are based on a split genome approach
that provides the viral genes necessary in trans for pro-
duction of viral particles in the helper/packaging cells
[15,16]. The viral particles are released into the cell cul-
ture supernatant (SN) and can be easily harvested with-
out need to disrupt the cells. Presently, the most
common method to concentrate these viral particles
from cell culture SN is UC [11,17]. In addition, different
methods have been studied to purify lenti- and retroviral
vectors including chromatography, ultrafiltration (UF)
and coprecipitation with salts and/or polymers
[11,18,19].
Here, we analyzed a purification system (LentiSE-
LECT, Sartorius Stedim Biotech, Goettingen, Germany)
that combines membrane adsorption and UF for the
concentration of VSV.G pseudotyped lenti- as well as
retroviral particles. The method used is based on bind-
ing of the viral particles to an anionic exchange mem-
brane adsorber (MA) followed by UF of the eluted
purified particles. Different volumes of cell culture SN,
up to 1,000 ml, can be purified and the resulting recov-
ery rates are reproducible and comparable to those
achieved by UC. Furthermore, the method was also suc-
cessfully applied for the purification of lentiviral parti-
cles without envelope proteins and retroviral particles
with an ecotropic envelope, demonstrating the broad
range of this application.
Results
Purification of lentiviral particles by using membrane
adsorbers
For purification of LVs, we initially focused on VSV.G
pseudotyped lentiviral particles, because they are the
most widely applied type of lentivectors. We used HIV-
derived LVs carrying a CMV promoter-driven eGFP
expression cassette [20] (Figure 1A). Viral particles were
generated by transient transfection of HEK 293T cells.
The cell culture SN was harvested and applied to anio-
nic exchange MAs (LentiSELECT, Sartorius Stedim Bio-
tech, Goettingen, Germany) to bind and enrich for virus
particles. Samples of each purification step were then
analyzed to quantify the amount of IPs by transduction
of HEK 293T cells and FACS analysis.
After loading of the lentiviral particles to the MA
and washing, retained viral particles were eluted with
high salt elution buffer (1 M sodium chloride). Given
the potential detrimental effect of high salt on the
functionality of the viral particles, we investigated the
impact of the hypertonic environment on viral infectiv-
ity. Incubation of the eluted LVs in the high salt buffer
for one hour on ice resulted in a significant reduction
of infectivity by 16.0 ± 6.4%. Within 2 hours 22.1 ±
6.4% of IPs were lost (Additional file 1, Figure S1). To
prevent loss of infectivity a buffer exchange step was
included to recover the viral particles in a buffer with
physiological salt concentration (e.g. Hank’sb u f f e r e d
salt solution (HBSS)). Buffer exchange as well as
further concentration of the viral particles was
achieved by using UF columns. The membranes of
these columns have pores of distinct size that can
retain viral particles, whereas smaller molecules and
particle fragments can pass through the pores.
Figure 1 Lentiviral vector construct and use of UF units with
different MWCOs for concentration of LVs. (A) Schematic
representation of lentiviral vector used. eGFP, enhanced green
fluorescent protein; CMV, promoter from cytomegalovirus; WPRE,
posttranscriptional regulatory element of woodchuck hepatitis virus;
cPPT, central polypurine tract; LTR, long terminal repeat; black
triangle, mutation in 3’ LTR, leading to self inactivation (SIN vector).
(B) Comparison of Vivaspin20 UF units with different MWCOs: 1,000
ml of cell culture SN were purified using the large MAs. The elution
fraction was desalted with Vivaspin20 UF units with MWCO of
100,000 (100 K) or 300,000 (300 K). The biological titer was
determined by FACS-analysis and the recovery rate (%) was
calculated. n = 4, mean + SEM. * 0.05 ≥ p > 0.01.
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were compared that can accommodate up to 20 ml of
MA eluate (Figure 1B). In both cases, only 1.5 ± 0.1%
of the viral particles were detected in the flowthrough.
Although UF units with a MWCO of 300 K require
less centrifugation time than the 100 K units due to
the larger pore size (data not shown), the 100 K unit
showed significant higher recovery of the viral particles
(recovery rate of 88.7 ± 3.1%). In summary, the Vivas-
pin20 UF unit with a MWCO of 100 K is suitable for
rebuffering, purifying as well as concentrating of the
lentiviral particles after elution from the MA.
Purification of lentiviral particles from small starting
volumes
Importantly, the use of anionic exchange MAs should
allow for the purification of lentiviral particles from
small as well as large starting volumes. First, we tested a
small volume system (LentiSELECT40), which can be
used for up to 40 ml starting solution. The viruses are
eluted by applying 4 ml elution buffer. Starting with 1.2
×1 0
9 ±1 . 8×1 0
8 IPs in the cell culture SN 55.5 ± 3.4%
of the viral particles applied were recovered from the
MA (Table 1 and Figure 2A). Approximately 11 and 9%
of virus was lost in the flowthrough and the wash frac-
tion, respectively (Figure 2A). Subsequently, the eluate
was loaded on the UF unit and the final volume of the
retentate was adjusted to ~360 μl (Table 1). Overall, the
final recovery rate of the small volume MA/UF combi-
nation was 48.7 ± 4.6% with 5.8 × 10
8 IPs in the con-
centrate (Table 1 and Figure 2A). Hence, a 4.5 fold
concentration was achieved with the MA and a further
13 fold concentration was obtained by UF (Table 1).
Taken together, the combination of anion exchange
resin and UF unit resulted in a 59 fold enrichment of
lentiviral particles from cell culture SN to concentrate.
High enrichment was also seen in Westernblot analysis
by using antibody against the lentiviral capsid protein
p24 (Additional file 2, Figure S2).
To compare the method presented here with a stan-
dard procedure, we used a well established UC protocol
[21] consisting of an initial centrifugation at 61,700 g
for 2 h, followed by loading the resuspended viruses on
a sucrose cushion. After a second spin at 53,500 g for 2
h, the viral precipitate was resuspended in ~330 μl
HBSS. Starting initially with 4.7 × 10
8 IPs in the cell cul-
ture SN 47.7 ± 4.8% of the IPs were recovered by UC
(Table 1 and Figure 2B), which is not significantly differ-
ent from the recovery rate obtained by use of the MA/
UF combination (p = 0.445).
Purification of lentiviral particles from large starting
volumes
Next, we tested whether larger volumes of cell culture
SNs can be processed with MAs. For this purpose, we
used a larger MA (LentiSELECT500) that can accom-
modate up to 500 ml starting volume. Using this MA/
UF setup 39.6 ± 5.5% (2.8 × 10
9 ±5 . 0×1 0
8 IPs in
approximately 1.1 ml) of the LVs were finally recovered
from the cell culture SN (Table 1 and Figure 2C). This
corresponds to a 193 fold enrichment of viral particles
in the concentrate compared to the starting solution.
Considering the differences in the reduction in volume
from SN to concentrate for the small and the large MA,
the overall enrichments are not significant different.
Using UC to purify viral particles from the same start-
ing volume of 500 ml of SN, a recovery rate of 40.1 ±
10.9% was achieved (Table 1 and Figure 2D). Again, no
significant difference between the recovery rates
obtained by the use of MA/UF setup and UC was
observed (p = 0.480).
It should be noted that for such large volumes UC is a
time-consuming procedure, because multiple centrifuga-
tion runs are necessary due to the limited capacity of
the rotors. For 500 ml cell culture SN the standard UC
protocol requires overall 4 runs each lasting 2 hours (3
times at 61,700 g with a loading volume of 180 ml per
run and a final concentrating run at 53,500 g). In
Table 1 Comparison of different methods for purification of LVs
SN elution concentrate
purification method volume
[ml]
IP/ml
(± SEM)
IP
(± SEM)
volume
[ml]
IP/ml
(± SEM)
IP
(± SEM)
volume
[ml]
IP/ml
(± SEM)
IP
(± SEM)
MA/UF
(n = 7)
40 3.0 × 10
7
(± 4.7 × 10
6)
1.2 × 10
9
(± 1.8 × 10
8)
4.7
(± 0.2)
1.3 × 10
8
(± 2.2 × 10
7)
6.2 × 10
8
(± 9.5 × 10
7)
355
(± 32)
1.8 × 10
9
(± 4.0 × 10
8)
5.8 × 10
8
(± 1.2 × 10
8)
UC
(n = 3)
40 1.2 × 10
7
(± 1.3 × 10
6)
4.7 × 10
8
(4.8 ± × 10
7)
- 327
(± 18)
6.8 × 10
8
(± 8.9 × 10
7)
2.1 × 10
8
(± 2.1 × 10
7)
MA/UF
(n = 6)
500 1.4 × 10
7
(± 8.6 × 10
5)
7.1 × 10
9
(± 5.2 × 10
8)
25.8
(± 0.2)
1.5 × 10
8
(± 3.5 × 10
7)
2.7 × 10
9
(± 3.5 × 10
8)
1064
(± 118)
2.7 × 10
9
(± 3.7 × 10
8)
2.8 × 10
9
(± 5.0 × 10
8)
UC
(n = 3)
500 2.5 × 10
7
(± 6.6 × 10
6)
1.3 × 10
10
(± 3.3 × 10
9)
- 776
(± 152)
6.1 × 10
9
(± 1.1 × 10
9)
4.6 × 10
9
(± 1.1 × 10
9)
MA/UF
(n = 3)
1000 1.8 × 10
7
(± 4.9 × 10
6)
1.9 × 10
10
(± 5.2 × 10
9)
40.6
(± 0.7)
1.7 × 10
8
(± 4.8 × 10
7)
7.0 × 10
9
(± 1.9 × 10
9)
1510
(± 220)
5.4 × 10
9
(± 1.8 × 10
9)
8.6 × 10
9
(± 3.6 × 10
9)
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Page 3 of 12contrast, loading, washing and elution of the MAs and
subsequent UF requires only around 3 h.
To test whether two large MA units can be serially
connected for further upscaling, we directly coupled two
units. To evaluate the efficiency of the serial MA set-up,
1,500 ml of cell culture SN were prepared and 1,000 ml
were loaded on two serially connected MAs and 500 ml
w e r el o a d e do nas i n g l eM A .T h ef l o w t h r o u g hw a s
collected stepwise in 50 ml fractions and the biological
titer (in IP/ml) was determined, respectively (Additional
file 3, Figure S3). The two set-ups showed increasing
concentrations of viral vectors in consecutive flow-
through fractions. For the single MA around 10% of the
initial viral load was in the flowthrough after adding
approximately 420 ml of cell culture SN onto the MA
(Additional file 3, Figure S3A). Similarly, for the two
Figure 2 Purification of LVs from different starting volumes. LVs were purified from 40 ml cell culture SN by using the small MA/UF setup
(A) or UC (B); from 500 ml of starting volume by application of the large MA/UF combination (C) or UC (D) and from 1,000 ml of cell culture
SN and use of two serially connected large MAs and UF (E). IP/ml were determined via FACS-analysis and the recovery rate (%) was calculated. n
= 7 (A), n = 3 (B); n = 6 (C), n = 3 (D), n = 3 (E). mean + SEM.
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Page 4 of 12coupled MAs 10% of the loaded viral particles were
found in the flowthrough after application of 850 ml of
starting volume (Additional file 3, Figure S3B). Thus,
the maximal loading volume is ~500 ml and ~1,000 ml
for one unit and for two coupled units, respectively. In
summary, a serial connection of two large MAs can be
used to increase the volume of loading material to up to
1,000 ml of cell culture SN. Purification of 1,000 ml of
cell culture SN with a two-MA-setup and UF (LentiSE-
LECT1000) resulted in a recovery rate of 43.6 ± 9.4%,
displaying an enrichment of almost 300 fold from start-
ing volume to concentrate (Table 1 and Figure 2E). This
is comparable to the enrichments achieved by the purifi-
cation of smaller SN volumes (40 ml or 500 ml) with
MA/UF considering the reduction in volume from SN
to concentrate.
Analysis of the purified lentiviral vectors
In order to analyze viral particle morphology and integ-
rity, we applied electron microscopy. The size and
appearance of particles purified by MA/UF were not dif-
ferent from those particles obtained by UC (Figure 3A-
C).
A further parameter to compare different purification
methods is the ratio of biological versus physical titer.
This ratio indicates the percentage of viral particles that
are actually infectious as compared to the overall viral
particles (physical titer). We determined the biological
titer by FACS analysis of transduced cells. The physical
titer (viral particles/ml, VP/ml) was quantified by two
methods that measure different constituents of the par-
ticles, i.e. the lentiviral capsid protein p24 or the viral
genome as measured with quantitative Realtime PCR
(QRTPCR). We analyzed the ratio of the biological and
the physical titer of LV preparations derived from purifi-
cations using either MA/UF or UC with different start-
ing volumes (Figure 3D). Overall the IP/VP ratios were
higher for the low volume preparations independently of
the purification method used and ca. 5 - 20% of the par-
ticles purified from low volumes were biologically active,
whereas only 1 - 9% purified from larger volumes were
infectious. These ratios are in the same range or even
higher than those found in the literature where ratios
between 0.1 to 1% were observed [22,23].
Comparison of the two purification methods revealed
also considerable variations: The IP/VP ratios for UC
are in the range of 7 - 20% and 9 - 13% for p24 and
QRTPCR method, respectively. For MA/UF the IP/VP
lies in the range of 4 - 6% and 1 - 5% for p24 and
QRTPCR, respectively. Statistical analysis of the
QRTPCR data showed that at high volumes there is a
significant difference between MA/UF and UC, but
there is no significant difference between the two purifi-
cation methods at low volumes (Figure 3D). In contrast,
the p24 data showed no significant difference between
MA/UF and UC after purifying large volumes and sig-
nificant difference between the two purification methods
at low volumes (Figure 3D). Thus, there is a consider-
able variation and even conflicting results between the
different assay methods available for the quantification
of the physical titer (i. e. total number of viral particles).
Nevertheless, one can conclude that the IP/VP ratios for
both UC and MA/UF are in the same range. Both meth-
ods exhibited a similar efficacy in purifying biologically
active viruses (see also Table 1) with a tendency of
higher IP/VP ratios after UC purification.
The purity of LV preparations is an important issue,
especially in clinical applications. Therefore, we analyzed
MA/UF preparations for their protein (Figure 3E) and
DNA content (Figure 3F). Use of DMEM with FCS for
culturing the packaging cells resulted in a high concen-
tration of proteins in the SN as well as in the concen-
trate presumably due to presence of serum proteins
especially albumin (molecular weight: 67 kDa). Next, we
tested whether serum free medium can be used for puri-
fication of LV containing SN. Two different serum-free
media (HyClone SFM4MegaVir and Panserin608) were
tested. These media clearly resulted in a reduction of
protein concentration in the SN with HyClone
SFM4MegaVir leading to the highest reduction of pro-
tein carry-over in the concentrate (Figure 3E). The IPs
applied to the protein gel were in the same range (1 to
3×1 0
5 IPs for SN and 1 to 2 × 10
7 IPs for the concen-
trate) indicating that use of serum free medium does
not influence the LV infectivity. Thus, cultivation of
producer cells after transfection can be performed with
serum free medium if reduction of the protein content
of the LV preparations is desired.
To determine DNA contaminations in the concen-
trate, we analyzed samples from LV purifications on an
agarose gel with and without treatment with benzonase
(Figure 3F) [24]. Without treatment with benzonase
(-benz, Figure 3F) high concentrations of DNA were
present in the LV concentrates. In contrast, benzonase
pretreatment of the SN efficiently reduces the DNA
content (+benz, Figure 3F). The biological titers of the
concentrates obtained with the two purifications were in
the same range (-benz: 1.3 × 10
9 IP/ml; +benz: 1.9 × 10
9
IP/ml), indicating that benzonase treatment does not
impair the biological activity of the LVs.
Concentration of non-VSV.G pseudotyped lentiviral
vectors
Presently, most LVs used are pseudotyped with VSV.G,
mainly due to its broad host range, high infectious titers
and stability during UC [1,15]. Nevertheless, for some
applications other envelope proteins are required
[25,26]. Furthermore, toxicity of VSV.G pseudotyped
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Page 5 of 12Figure 3 Analysis of the purified LVs. Cell culture SN was purified by UC or MA/UF. The concentrates were analyzed by electron microscopy:
40 ml SN, MA/UF (A); 500 ml SN, MA/UF (B); 500 ml SN, UC (C). (D) Analysis of biological vs. physical titer (IP/VP) of different LV preparations:
The biological titer was determined via FACS-analysis of transduced cells and the physical titer by use of a HIV-1 p24 Antigen ELISA (p24 ELISA)
or QRTPCR (Realtime). Values were determined in triplet and/or use of different dilutions. Concentrates of the following purifications were
analyzed: 500 ml SN, MA/UF (n=7 ); 500 ml SN, UC (n=3 ); 40 ml SN, MA/UF (n=4 ); 40 ml SN, UC (n=7 ). mean+SEM. * 0.05 ≥ p > 0.01; ***
0.001 ≥ p; ns - not significant. (E), (F) Analysis of protein and DNA content of LV preparations. After transfection of producer cells the medium
was changed to 40 ml DMEM, supplemented with FCS (DMEM) or to serumfree medium Panserin 608 (Pans) or HyClone SFM4Megavir (SFM).
Purification of LVs was performed by MA/UF. 10 μl of SN or concentrate (conc) as well as 5 μg pure BSA was loaded on the SDS-PAgel
(coomassie blue stain). M, protein marker (E). 500 ml of the same cell culture SN was each incubated at 37°C for 30 min either without addition
of benzonase (-benz) or after adding 12.5 u/ml benzonase (+benz). The SN was purified using MA/UF, respectively. 5 μl of the elution fraction
(el) or the concentrate (conc) were used for agarose gel electrophoresis. M, DNA marker (F).
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upon systemic administration has been observed [13,27].
Therefore, we tested whether the VSV.G envelope is
required for purification with the MA system. Cell cul-
ture SNs containing viral particles either with VSV.G
envelope or without envelope were each purified with
the small MA/UF system and samples were analyzed by
p24-ELISA (Figure 4A). Similar titers in the SN
(approximately 2.2 × 10
9 VP/ml) and nearly no viral
particles were found in the flowthrough in both cases.
Although significant higher titers were obtained with
VSV.G pseudotyped viral particles, this experiment
clearly shows that VSV.G is not required for binding to
the adsorber material.
Purification of oncoretroviral vectors
Retroviral vectors have been established from different
retroviruses. They play an important role in gene ther-
apy [1]. Among the retroviruses, oncoretroviruses repre-
sent presently the most commonly used vector type.
Therefore, we tested whether the MA system can also
be applied for the purification of oncoretroviral vectors.
We used MoMLV-derived vectors containing an eGFP
expression cassette under control of the MoMLV-LTR
(Figure 4B) [28]. In initial experiments, VSV.G pseudo-
typed retroviral as well as VSV.G pseudotyped lentiviral
particles were purified in parallel using 40 ml of cell cul-
ture SN and the small MA/UF combination, respec-
tively. The recovery rate for the VSV.G pseudotyped
retrovirus as analyzed by FACS was almost 30% (data
not shown) demonstrating the utility of the MA system
also for this vector system.
Although retroviruses that carry the ecotropic envel-
ope have a narrow host range, this type of vector is also
widely used [11]. Therefore, we tested the MA/UF setup
for the purification of 40 ml cell culture SN containing
ecotropic oncoretroviral vectors. For comparison, we
additionally analyzed oncoretroviral vectors with VSV.G
envelope. Samples were analyzed using a C-type RT
activity kit (Figure 4C). In the elution fraction 38.5 ±
1.3% of the VSV.G pseudotyped particles and 29.8 ±
2.5% of the retroviral particles with ecotropic envelope
were recovered, respectively. After the UF, the recovery
rate of the ecotropic virus was 10.0 ± 0.3% whereas 19.2
± 0.7% of the initially applied VSV.G pseudotyped parti-
cles were detected in the concentrate.
In summary, these data indicate that VSV.G is not
necessary for binding to the MA and that also purifica-
tion of viral particles pseudotyped with other envelope
proteins is possible. Although binding to the adsorber
works best with VSV.G envelope, these results demon-
strate the broad application spectrum of the MA/UF
system presented in this study.
Discussion
Here, we describe a method for purification and concen-
tration of lentiviral as well as oncoretroviral particles.
Due to their capability of integrating their RNA after
reverse transcription into the host genome, recombinant
retroviral vectors are versatile tools in a broad spectrum
of applications. LVs have become a convenient alterna-
tive to oncoretroviral vectors, because of their ability to
transduce dividing as well as non-dividing cells.
Presently, the most common way of concentrating
VSV.G pseudotyped viral vectors is UC. However, purifi-
cation methods based on UC are difficult to scale up
and time-consuming due to the limited capacity of the
centrifuges. Furthermore, impurities having a similar
density as the viral particles (membrane vesicles of the
host cells e. g.) are coprecipitated during the centrifuga-
tion steps [29,30]. Alternatively, chromatography can be
applied for vector concentration, including affinity chro-
matography, anion exchange and size exclusion. Chro-
matography is a very useful procedure to separate
macromolecules like DNA, proteins and also viral vec-
tors. But many chromatographic media are inapplicable
because of the relatively labile nature of lenti- and retro-
viral vectors [11]. Affinity chromatography strategies are
based on streptavidin-biotin interaction [31], heparin
binding [32] and immobilized metal affinity [33]. In
anionic exchange chromatography the negatively
charged viral vectors bind to the positively charged
chromatographic material. Bound virus can be then
eluted by high salt buffer [11,18,34]. Elution with high
Figure 4 Comparison of lenti- and retroviral vectors with
different pseudotypes. (A) LV production was either performed
with (+) or without (-) VSV.G pseudotyping and 40 ml of the cell
culture SN were purified using MA/UF and analyzed by p24-ELISA,
respectively. The viral particles per ml were calculated (n = 3, mean
+SEM). (B) Schematic representation of oncoretroviral vector used.
eGFP, enhanced green fluorescent protein; LTR, long terminal
repeat. (C) Oncoretroviral vectors were produced with VSV.G
pseudotyping (VSV.G) or ecotropic envelope (ecotrope) and 40 ml
of cell culture SN were each purified using MA/UF setup. The
physical titer of the fractions was analyzed using C-type RT-activity
kit and the recovery rate was calculated, respectively. n = 3, mean
+SEM. * 0.05 ≥ p > 0.01; *** 0.001 ≥ p.
Zimmermann et al. BMC Biotechnology 2011, 11:55
http://www.biomedcentral.com/1472-6750/11/55
Page 7 of 12salt buffers significantly reduces the infectivity of viral
vectors, very likely due to an increase in osmotic pres-
sure and a subsequent damage of the viral membrane.
We found that only one hour of exposure to high salt (1
M NaCl) on ice is enough to inactivate 16.0 ± 6.4% of
the LVs (Additional file 1, Figure S1). Others observed a
reduction by 50% of infectious retroviral particles when
exposed to high salt for one hour at room temperature
[32]. Therefore, further purification steps are necessary
[32]. However, anionic exchange requires no modifica-
tion of the viral vectors such as biotinylation or his-tag-
ging and is fast, versatile and easy to scale up [11,35,36].
Several anion-exchange chromatographic matrices have
already been investigated with different binding capaci-
ties for retroviral particles [37]. Another chromato-
graphic procedure is size exclusion. Although it is a very
powerful separation method, it is mainly applied as a
polishing step due to difficulties in up-scaling and a low
throughput [11,38]. Another way to purify lenti- and
retroviral vectors is UF through membranes with various
pore sizes (20-500 kDa). Although UF is a fast and sim-
ple purification method, an u n d e s i r a b l es i d ee f f e c ti s
concentration of macromolecules derived from cell deb-
ris [39]. Further alternatives for purifying lenti- and ret-
roviral particles are precipitation with salt buffers
(ammonium sulphate, calcium phosphate) and/or poly-
mers (e.g. polyethylene glycol, poly-L-lysine). But this
method has the disadvantage that the salts and polymers
as well as impurities (e.g. cell debris) are co-sedimented
and therefore, additional purification steps are often
necessary. Furthermore, this method has a low selectiv-
ity and is difficult to scale up [11,40].
Here, we used a combination of anionic exchange
and UF for the purification of VSV.G pseudotyped
lenti- and retroviral particles. The virus was bound to
the cationic membrane by loading the cell culture SN
to the MA. Elution of the viral particles was achieved
by application of high salt buffer. However, due to
toxic effects of salt buffers with high molarity [32,38]
subsequent rebuffering is necessary. We used UF units
for desalting and concentration, leading to high titer
LV preparations with a biological titer in the range of
2t o5×1 0
9 IP/ml.
MAs of different capacity were applied to purify 40 ml
and 500 ml of cell culture SN, respectively. The number
of infectious lentiviral particles obtained in the concen-
trates after MA/UF was similar or even higher as com-
pared to preparations purified with UC of the same
starting volume (Additional file 4, Figure S4). Impor-
tantly, the MA/UF system allows for purification of up
to 1,000 ml of starting volume containing LVs by a
serial coupling of two large MAs and final UF. Further-
more, the MAs used in our study can be connected to
FPLC (data not shown). This enables an automation of
the purification procedure as well as monitoring of dif-
ferent parameters like UV extinction or conductivity.
For use of LVs in clinical trials (e. g. [41]), high titer
vector preparations are needed that can be reproducibly
obtained at large scale. Impurities that derive from
transfection and cell debris of producer cells as well as
medium components should be minimized in the LV
preparations for such applications. In addition, some
primary cells (e.g. primary cortical neuronal cultures)
have been shown to be sensitive to toxic effects of FCS
components supplemented in the medium [42]. In this
c o n t e x ti ti so fi n t e r e s tt h a tw eo b s e r v e dac l e a rr e d u c -
tion of protein and DNA contaminants by use of serum
free medium and after treatment of cell culture SN with
benzonase, respectively (Figure 3E and 3F) [24,43].
Another important property of LV preparations is the
r a t i oo fi n f e c t i o u sv s .t o t a lv i r a lp a r t i c l e s .O v e r a l l ,w e
observed that between 1 and 20% of the purified parti-
cles were biologically active, which is similar or even
better than already published IP/VP ratios (0.1 to 1%)
[22,23]. These differences might be due to various pro-
tocols for LV preparation and purification procedures as
well as cell lines and constructs used.
Different set ups for the cultivation of the adherent
HEK 293T packaging cells have been described in the
combination with MAs. For example Kutner et al pub-
lished a combination of multilayered flasks with a gas
permeable growth surface (called HYPERFlask vessels)
and anionic exchange chromatography [35]. Cultivation
of the packaging cells in the HYPERFlask vessels,
instead of conventional cell culture dishes, resulted in
10 fold increased LV production [35]. Furthermore, LV
generation of cells in suspension culture were recently
analyzed by Lesch et al to facilitate a scalable LV pre-
paration for gene therapy applications [44]. For this pur-
pose, baculovirus based LV production of suspension
cells was used for transduction of the packaging cells
with the lentivector/packaging plasmids instead of the
commonly applied transfection of adherent cells by cal-
ciumphosphate. However, in order to remove the bacu-
loviruses a purification step had to be included [44].
It remains to be shown that these systems can also be
used for particles carrying different envelopes and for
vectors derived from oncoretroviruses.
An outstanding feature of the purification method
described herein is that it can be applied for the purifi-
cation of lenti- as well as oncoretroviral vectors.
Although a direct comparison between viral vectors
derived from different members of the retrovirus family
is not feasible (e.g. transgene expression driven by CMV
versus LTR elements in the lentiviral and retroviral vec-
tors, respectively), the recovery rates obtained with the
VSV.G pseudotyped retrovirus is in the similar range as
the recovery of VSV.G pseudotyped lentiviruses.
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envelopes can be purified, which broadens the spec-
trum of possible applications considerably. Apart from
VSV.G also other glycoproteins were shown to be use-
ful for pseudotyping lentiviral particles including envel-
ope proteins from ross river virus, semliki forest virus,
mokola virus or rabies virus [45,46]. Initially, we
showed that purification of LVs is possible even with-
out any envelope protein showing that the presence of
VSV.G is not a perquisite for LV purification and
opening the possibility of alternative pseudotyping. In
this context is of interest that the MA/UF system can
also be used to purify viral particles carrying an eco-
tropic envelope. However, purification of the oncore-
troviral particles with VSV.G pseudotyping resulted in
a significant higher recovery rate compared to ecotro-
p i ce n v e l o p ep r o t e i n .T h i sd i f f e r e n c em i g h tb ed u et o
reduced stability of ecotropic pseudotyped viral parti-
cles [11]. In general, the lenti- and retrovirus stability
depends not only on the particular envelope protein
but also on the producer cell line type from which the
viral lipid envelope was derived [9,13] and other fac-
tors like buffers, pH, shear forces, temperature and
especially presence of high salt concentrations
[32,37,43].
Conclusions
The MA/UF method described here is a versatile way to
purify high titer lentiviral as well as oncoretroviral parti-
cles starting from small and large volumes. With the
MAs described a broad range of starting volumes up to
one liter of virus supernatant can be rapidly processed.
Importantly, even at large scale/higher input volumes
the method yields reproducibly high virus titers.
Furthermore, the procedure is easy to handle and can
even be connected to an automated purification system
such as FPLC allowing for monitoring accurate salt gra-
dient elution, which is an important factor for further
use in a clinical setting. In contrast to the widely used
UC method, no expensive equipment like ultracentri-
fuges are needed.
Importantly, this method can be used for vectors
derived from different members of the large family of
retroviruses independently of the envelope (pseudotyp-
ing) used. Taken together, the MA/UF combination
described in this study offers a flexible and rapid way to
purify lentiviral particles as well as oncoretroviral vec-
tors with different pseudotypes from a broad range of
starting volumes at reproducibly high titers.
Methods
Unless stated otherwise, all chemicals and biochemicals
used in this study are from highest purity (tested for cell
culture).
Viral vector preparation
The original virus plasmids of the 3
rd generation are
derived from the lab of Inder Verma (The Salk Institute
for Biological Studies, Laboratory of Genetics, La Jolla,
CA, USA). The lentivector system consists of two major
parts: the vector and the packaging constructs. The used
lentivector rrl-CMV-eGFP (Figure 1A) contains a CMV-
driven eGFP expression cassette. The promoter/enhancer
sequences in the U3 region of the 3’ LTR were deleted to
generate self-inactivating (SIN) vectors [47]. The used
oncoretroviral vector pCLMFG-GFP (Figure 4B) is based
on MoMLV with an eGFP expression cassette driven by
the MoMLV-LTR [28]. The packaging system used for
LV production was described in detail previously [16].
Oncoretroviral particles were produced with the CMV-
gag/pol packaging plasmid [28] and for pseudotyping
either VSV.G or ecotropic envelope was used.
Production of recombinant virus
The production of LVs was performed as described pre-
viously [21]. Briefly, HEK 293T cells were seeded on
poly-L-lysine coated 150 cm
2 cell culture dishes (BD
Falcon, Franklin Lakes, NJ, USA) or 5 chamber cell
stacks (surface area in sum 3180 cm
2; Corning Incorpo-
rated, Lowell, MA, USA) in DMEM (Invitrogen, Darm-
stadt, Germany), supplemented with 10% fetal calf
serum (Biochrom, Berlin, Germany), 100 U/ml penicillin
G/100 μg/ml streptomycin (Pen/Strep; Biochrom, Berlin,
Germany) and incubated at 10% CO2 and 37°C. Cells
were transfected at ~50% confluency by calciumpho-
sphate transfection with 22.5 μg lentivector, 14.6 μg
pMDLg/pRRE, 5.7 μg RSV-rev and 7.9 μg pMD.G (VSV.
G) per 150 cm
2 cell culture dish. Amounts for cell fac-
tories were calculated according to the surface area (one
5 chamber cell stack is equivalent to 21.2 150 cm
2 cell
culture dishes). For production of oncoretroviral vectors
transfection was performed using 25 μg retroviral vector
pCLMFG-GFP, 12.5 μg pMD.G or CMV-ecotrope and
25 μgC M Vgag/pol per 150 cm
2 cell culture dish. For
transfection, cells were cultured at 3% CO2 and 37°C
over night. On the next morning, the medium was
replaced by 20 ml fresh supplemented DMEM per 150
cm
2 dish and 350 ml per cell factory. For analysis of
protein content medium was replaced by serum free
medium (HyClone SFM4MegaVir, Thermo Fisher Scien-
tific, Waltham, MA, USA or Panserin 608, PAN Biotech,
Aidenbach, Germany), supplemented with Pen/Strep.
Cells were cultured again at 10% CO2 and 37°C.
Purification of recombinant virus
For purification of viral vectors, cell culture SN was col-
lected 24 h after adding fresh medium. To remove cell
debris the SN was filtered either using a bottle-top filter
(SFCA, 0.45 μm, Nalgene, Thermo Fisher Scientific,
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Page 9 of 12Waltham, MA, USA) or the Sartopore 2 150-filter (PES,
0.45 μm-0.2 μm, Sartorius Stedim Biotech, Goettingen,
Germany).
The components and buffers necessary for the purifi-
cation using MA/UF are commercially available as Len-
tiSELECT kits for different starting volumes of cell
culture SN (40 ml: LentiSELECT40; 500 ml: LentiSE-
LECT500; 1,000 ml: LentiSELECT1000). The purifica-
tion procedure was performed according to the
manufacturer’s manual (Sartorius Stedim Biotech, Goet-
tingen, Germany).
The UC protocol was described previously [21].
Briefly, the filtered solution was transferred to centrifu-
gation tubes and centrifuged in an ultra-centrifuge
(Optima L-100 XP, Beckman Coulter Incorporated,
Brea, CA, USA) with SW32Ti rotor (Beckman Coulter
Incorporated, Brea, CA, USA) for two hours at 19,400
rpm and 17°C. Subsequently, virus pellets were resus-
pended in HBSS (Invitrogen, Darmstadt, Germany) and
combined. The pre-concentrated suspension was trans-
ferred into a centrifuge tube and layered on top of a 2
ml 20% (w/v) sucrose cushion. The tubes were centri-
fuged using a SW55 rotor (Beckman Coulter Incorpo-
rated, Brea, CA, USA) for 2 hours at 21,000 rpm at 17°
C. The pellet was resuspended in an appropriate volume
of HBSS. The tube was vortexed for 45 minutes at 1,400
rpm and 17°C, followed by a short centrifugation step (3
s, 16,000 g) to pellet debris. Finally, the opaque SN was
transferred to a new tube.
For both methods, samples were taken from every
purification step and used for the transduction of cells
(see also analysis of viral titer) or stored at -80°C for
further analysis.
Analysis of viral titer
The biological titer of the LVs carrying the eGFP repor-
ter was analyzed by transduction of HEK 293T cells fol-
lowed by flow cytometry and IP/ml were calculated as
previously described [21]. For analyzing the physical
titers of the LV containing solutions either the HIV-1
p24 Antigen ELISA from Zeptometrix Corporation (Buf-
falo, NY, USA) was used to measure the amount of the
lentiviral p24 capsid protein according to the manufac-
turer’s instructions or QRTPCR was applied to deter-
mine the viral RNA genome [23]. For calculating the
viral particles per ml (VP/ml) from p24 concentration
the following term was used according to manufacturer’s
manual: VP/ml = pg p24/ml × 10,000. Measurements
were each done from different dilutions of LV prepara-
tions. To establish a calibration curve for QRTPCR mea-
surements the lentiviral plasmid rrl-CMV-GFP (Figure
1A) of known concentration (measured by spectropho-
tometry) was used and standards were generated by
applying 10-fold serial dilutions. The number of DNA
molecules was each determined by including molecular
weight of the plasmid, Avogadro constant and dilution
factor. The plasmid was amplified by QRTPCR using
specific TaqMan
® primers for lateRT (for: 5’-TGTGT
GCCCGTCTGTTGTGT-3’;r e v :5 ’-GAGTCCTGCGTC
GAGAGAGC-3’) and lateRT probe (5’-FAM-CAGTGG
CGCCCGAACAGGGA-BHQ1-3’). Ct values measured
were plotted against the number of plasmid DNA mole-
cules and a standard curve was generated (Additional
file 5, Figure S5). Ct values were determined at least in
triplet. For measurement of samples RNA was isolated
from the concentrated LV preparations by use of mir-
Vana™ miRNA Isolation Kit according to the manufac-
turer’s instructions (Applied Biosystems, Carlsbad, CA,
USA). RNA was transcribed into cDNA using Tran-
s c r i p t o rF i r s tS t r a n dc D N AS y n t h e s i sK i tf r o mR o c h e
Diagnostics (Mannheim, Germany) according to the
manual. QRTPCR was then performed with TaqMan
®
probe and primers as described before. By using the
calibration curve the viral particles per ml were calcu-
lated from the Ct values considering the diploid lenti-
viral RNA genome. Measurements were each done in
triplet from three different dilutions of LV preparations.
In case of oncoretroviral particles the C-type RT-activ-
ity kit from Cavidi AB (Uppsala, Sweden) was used to
analyze the activity of viral reverse transcriptase. Proce-
dure was performed from different sample dilutions
according to the manufacturer’s manual. Reverse tran-
scriptase activity was measured colorimetric in mu/ml.
Protein gel electrophoresis and Western blot analysis
For analysis of protein content LV containing fractions
were loaded onto SDS-protein gel and coomassie blue
stained [48]. For detecting viral particles via Western
blot analysis antibody against lentiviral capsid protein
p24 was used. Viral particles containing fractions were
applied to SDS-protein gel and immunoblotting on a
PVDF-membrane was performed. Blocking of membrane
was achieved with 5% (w/v) skimmed milk powder in
PBS (phosphate buffered saline). Polyclonal antibody to
HIV1 p24 (abcam, Cambridge, UK) was applied 1:2,000
in TBS (Tris-buffered saline) with 1% (v/v) Tween20
(TBST) for 2 h at room temperature. After washing,
peroxidase-conjugated second antibody Anti-Rabbit IgG
(0.8 mg/ml; dianova, Hamburg, Germany) was used
1:10,000 in TBST (1 h at room temperature). For ima-
ging, chemiluminescent substrate for horseradish peroxi-
dase (Thermo Fisher Scientific, Waltham, MA, USA)
was applied.
Agarose gel electrophoresis
For detection of coeluted DNA LV containing fractions
were loaded onto 0.7% (w/v) agarose gel and electro-
phoresis was performed in 1x TBE (Tris/borate/EDTA)
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Page 10 of 12buffer. The gel was stained with ethidium bromide and
analyzed using a gel documentation system [48].
Electron microscopy
Images of purified viral particles were made using elec-
tron microscopy with negative staining procedure. The
viral particles were mixed with 1% (v/v) glutaraldehyde
solution and a droplet was placed on parafilm for 10
min. A formvar covered 200 mesh grid coated with car-
bon (Plano GmbH, Wetzlar, Germany) was placed on
the droplet for 5 min. Remaining solution was soaked
with a filter paper. The grid was then placed on a dro-
plet of phosphotungstic acid for 30 min and excess
liquid was again soaked with a filter paper. After drying,
the grid was put into the transmission electron micro-
scope Philips CM 10 with digital imaging analySiS from
SIS (Olympus Europa GmbH, Hamburg, Germany) and
images were taken.
Additional material
Additional file 1: Figure S1. Effect of high salt elution buffer. High
salt elution fractions were used for transduction of HEK 293T cells and
thereafter incubated on ice for 0.5 h, 1 h, 1.5 h and 2 h and utilized
again for infection. The biological titer was determined and the recovery
was calculated in relation to IPs at the beginning, respectively. n=3 ,
mean +SEM. * 0.05 ≥ p > 0.01; ** 0.01 ≥ p > 0.001.
Additional file 2: Figure S2. Westernblot-analysis of LV purification
using MA/UF combination. 40 ml of LV containing cell culture SN was
purified using MA/UF setup and 15 μl of cell culture SN (SN), elution
fraction (elution) as well as concentrate (conc) were loaded on SDS-
protein gel and Westernblot was performed with p24-antibody. One
representative blot (of n = 4) is shown.
Additional file 3: Figure S3. Capacity of large MAs. 500 ml (A) or
1,000 ml (B) of the same cell culture SN were purified using the large
MA (A) or two serial connected large MA-units (B). After applying the
starting solution the flow through was collected in 50 ml-steps and the
biological titer was determined, respectively.
Additional file 4: Figure S4. Comparison of MA/UF combination and
UC. Cell culture SN (40 ml or 500 ml) containing VSV.G pseudotyped LVs
were purified either by using MA/UF setup (40 ml SN: n=7 ; 500 ml SN:
n=6 ) or UC (40 ml SN: n=3 ; 500 ml SN: n=3 ). The biological titer of
the concentrates was each determined using FACS-analysis and IPs were
calculated. *** 0.001 ≥ p.
Additional file 5: Figure S5. Calibration curve for quantification of
LVs using qRealtime PCR. The lentiviral plasmid rrl-CMV-GFP (Figure 1A)
was amplified by QRTPCR using specific TaqMan
®® primers and probe.
Plasmid concentration was determined by spectrophotometry and
standards were generated by using 10-fold serial dilutions. Ct values
measured were plotted against the number of plasmid DNA molecules
and a standard curve was generated (y = -1.405 ln (x) + 39.747). Ct
values were determined at least in triplet (mean ± SEM).
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